Radiopharmaceutical company Lantheus Holdings (NASDAQ:LNTH) will be reporting results this Thursday before the bell. Here’s what investors should know.
Lantheus beat analysts’ revenue expectations last quarter, reporting revenues of $377.3 million, up 1.2% year on year. It was a satisfactory quarter for the company, with a beat of analysts’ EPS estimates but full-year revenue guidance missing analysts’ expectations.
Is Lantheus a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Lantheus’s revenue to decline 4.7% year on year, in line with the 4.1% decrease it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. Lantheus has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at Lantheus’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 5.8%, beating analysts’ expectations by 0.5%, and Baxter reported revenues up 5.3%, topping estimates by 6%. GE HealthCare traded up 9.1% following the results while Baxter was also up 5.6%.
Read our full analysis of GE HealthCare’s results here and Baxter’s results here.
Investors in the healthcare equipment and supplies segment have had steady hands going into earnings, with share prices up 1.4% on average over the last month. Lantheus is down 1.8% during the same time and is heading into earnings with an average analyst price target of $107.22 (compared to the current share price of $100.97).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.